Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-8539 dose-ranging trial in overactive bladder
NL-OMON33831Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ONO-8539 in overactive bladder (OAB) (5 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Mean change from baseline in number of micturitions per 24 hours at 12 weeks. Started Jul 2009; status: active, not recruiting.
02
Drugs
ONO-8539
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON33831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33831.